Synereca Pharmaceuticals was selected to present as a finalist in the Southeastern BIO Investor Forum Early Stage Shootout. More than 300 investors, industry representatives, academics and life science service providers attended the Eleventh Annual Southeastern BIO Investor Forum on December 3-4th in Charleston, South Carolina. The Forum is the Southeast’s premier life sciences venture capital conference.
The Early Stage Shootout attracted 41 entrants from throughout the southeast. Sixteen companies were invited to attend this years Investor Forum in Charleston and make panel presentations. The panelist then chose the four best opportunities, which included Synereca, to make presentations to the entire SEBIO Investor Forum audience.
Synereca Pharmaceuticals was created to address the growing problem of bacterial resistance to current antibiotics by developing orally active drugs that restore or increase the effectiveness of existing antibiotics. Synereca is a spin-out from the research of Dr. Scott Singleton at the UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. The company’s initial program focuses on inhibiting RecA, a key enzyme in bacterial DNA repair as well as in the development and transmission of antibiotic resistance. Prototype RecA inhibitors potentiate the killing of a wide variety of pathogenic bacteria by a broad range of bactericidal antibiotics.
SEBIO’s Investor Forum celebrated the growth of the life sciences industry in the Southeast. Investors, entrepreneurs, researchers, and companies interfacing with the industry met to honor the productivity of newly formed and established companies in the region as well as to formulate strategies to foster growth in the coming decade. This year’s Forum brought investment banks, seasoned venture capital funds, and large and intermediate pharmaceutical companies together with newly emerging companies and research institutions to discuss the opportunities and prospects for growth over the course of the next few years.